Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
To me
Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company developing prescription cannabinoid medicines, announces that it has been informed that Clarissa Sowemimo-Coker, the Chief Executive Officer of the Company, and Julie Pomeroy, the Company's Non-Executive Chair, have today purchased ordinary shares of £0.001 ("Ordinary Shares") in the Company.
Recent raise was .5 remember
https://www.londonstockexchange.com/news-article/OCTP/directors-dealings/16349345
To test .50
Looking better with some chunky buys
Would be nice to get an update Monday and start moving back toward 0.7
That’s how it looks , I thought this year was meant to be a healthy news flow etc as Clarissa stated , I’m starting to doubt her integrity now
A shame. Thought with product getting through phase 1 this would be higher. Seems as though market still doubts OCTP on funding possibly.
It's a pity we cannot hold on to our Redenominated Shares and sell our deferred shares of 0.9p actually at 0.9p. That would be good.
£11..... noone interested about this stock. :😮
RNS Number : 6518D
Oxford Cannabinoid Tech.Holdings
19 February 2024
Oxford Cannabinoid Technologies Holdings plc
("OCTP" or the "Company")
Result of General Meeting
Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company developing prescription cannabinoid medicines, announces that the resolution set out in the notice of General Meeting ("GM") dated 2 February 2024 was passed at the GM held at the offices of Penningtons Manches Cooper LLP, 125 Wood Street, London EC2V 7AW on Monday 19 February 2024.
Morning all. Blue week ahead
Two big delayed buys? About £40ks worth
They look like buys to me anyways ?
Maybe we finally get some movement
And what to do with the Deferred Shares?
As a result of the Capital Reorganisation, Shareholders will receive 1 Redenominated Share and 1 deferred share of 0.9p ("Deferred Share") in substitution for every 1 Existing Ordinary Share held.
I think we will see this creep higher from here as more and more people load up
Live ASK ticked up a bit. Few more of them and it'll be off to the races
Looks like bottoms in.
I’m gunna start loading up at these levels.
Good luck all
DYOR
Must admit that the talk of further dilution to raise capital by end 24 worries me … as does the idea they could create 200% more share diluting out share value by two thirds. I know it’s worst case but … worrying
Really enjoyed the read from the Edison broker note. Some extremely useful information in there and some very mouth watering targets
Expect this to come to life soon
𝐕𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧: 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧𝐞𝐝 𝐚𝐭 £𝟐𝟓.𝟑𝐦 𝐨𝐫 𝟐.𝟔𝐩
Key highlights included the initiation and subsequent positive safety data from @OxCanTech first Phase I clinical trial and a foray into oncology
https://www.edisongroup.com/research/early-signs-of-revival-in-clinical-activity/33216/
Hi chrishutch, totally agreed at this ridiculous price an incredible opportunity to buy at sub 0.005p Given the poor fund rise by the BOD no doubt they will be filling their boots.
Expect the usual positive RNS to land shortly after the raise and should easily bounce back to near 1p. Not good for existing holders like me but I have also taken the opportunity in average down below 0.0048ish making my long term hold here better average.
Amazed how many people can’t see the value in the current price. This is not a keep the lights on moment, this was clever and backed by strength.
I firmly believe we will see a bag or two in the coming months
Currently.
Time to buy in, average down, or take advantage. This is going to be worth more very soon.